Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Mar 24
8-K
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
8 Dec 23
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
15 Nov 23
UPLOAD
Letter from SEC
14 Nov 23
S-3
Shelf registration
13 Nov 23
8-K
IGM Biosciences Announces Third Quarter 2023 Financial Results
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Departure of Directors or Certain Officers
3 Oct 23
8-K
IGM Biosciences Announces Second Quarter 2023 Financial Results
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
D
Exempt offering of security
7 Jul 23
8-K
Departure of Directors or Certain Officers
27 Jun 23
8-K
Entry into a Material Definitive Agreement
23 Jun 23
424B5
Prospectus supplement for primary offering
23 Jun 23
FWP
Free writing prospectus
22 Jun 23
424B5
Prospectus supplement for primary offering
22 Jun 23
FWP
Free writing prospectus
21 Jun 23
8-K
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
21 Jun 23
8-K
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
S-8
Registration of securities for employees
30 Mar 23
8-K
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
30 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
21 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Results of Operations and Financial Condition
6 Jan 23
EFFECT
Notice of effectiveness
15 Nov 22
CORRESP
Correspondence with SEC
9 Nov 22
UPLOAD
Letter from SEC
9 Nov 22
S-3
Shelf registration
3 Nov 22
8-K
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
3 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
424B3
Prospectus supplement
8 Aug 22
Latest ownership filings
4
Steven Weber
15 Mar 24
4
Chris H Takimoto
15 Mar 24
4
Misbah Tahir
15 Mar 24
4
Fred Schwarzer
15 Mar 24
4
Bruce Keyt
15 Mar 24
4
Lisa Lynn Decker
15 Mar 24
4
Jeremy Green
14 Mar 24
4
Michael Stewart Lee
14 Mar 24
4
Steven Weber
14 Mar 24
4
Chris H Takimoto
14 Mar 24
4
Misbah Tahir
14 Mar 24
4
Fred Schwarzer
14 Mar 24
4
Bruce Keyt
14 Mar 24
4
Lisa Lynn Decker
14 Mar 24
4
Jakob Haldor Topsoe
14 Mar 24
4
Christina Teng Topsoe
14 Mar 24
4
Elizabeth H.Z. Thompson
14 Mar 24
4
William Strohl
14 Mar 24
4
Julie Hambleton
14 Mar 24
4
M KATHLEEN BEHRENS
14 Mar 24
4
JULIAN BAKER
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Bruce Keyt
5 Mar 24
4
Jeremy Green
1 Mar 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
12 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
12 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G
FMR LLC
9 Feb 24
4
Michael Stewart Lee
3 Jan 24
4
Jeremy Green
3 Jan 24
4
Jakob Haldor Topsoe
3 Jan 24
4
Christina Teng Topsoe
3 Jan 24
4
M KATHLEEN BEHRENS
3 Jan 24
4
JULIAN BAKER
3 Jan 24
4
Fred Schwarzer
15 Dec 23
4
Bruce Keyt
15 Dec 23
4
Lisa Lynn Decker
15 Dec 23
4
JULIAN BAKER
15 Dec 23